200 results about "Lost Weight" patented technology

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

Disclosed herein are methods for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity using a glucagon-like peptide-1 (GLP-1) receptor non-peptide agonist (NPA) compound selected from Compound 1, Compound 1a, Compound 2, Compound 3, pharmaceutically acceptable salts thereof, and hydrates of the compounds and pharmaceutically acceptable salts, by oral administration to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA. Also disclosed herein are uses of a GLP-1 receptor NPA compound for the manufacture of a medicament for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA.

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

To provide a more effective medicament which is potent in vitro and potent against weight loss, which at the same time does not result in proportionally increased levels of side effects, which has improved pharmacokinetic properties, which has improved chemical stability, which is suitable for once weekly administration in humans, and / or which is suitable for oral administration.SOLUTION: The present invention relates to a GLP-1- / GIP- / amylin-receptor tri-agonist. This GLP-1- / GIP- / amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.SELECTED DRAWING: None

The invention relates to the technical field of food nutrition and health care and biological medicines, in particular to application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicines for treating and / or preventing obesity and / or body weight super-severe illness and digestion-aiding health food. According to the experimental results, high-glucose and high-fat rats are continuously fed in the stomach for 8 weeks, and the food intake can be effectively reduced and the body weight can be reduced through preventive administration; the conclusion that beta-1, 3 / alpha-1, 3-glucan has the digestion-aiding health-care food function can be obtained according to the requirements of'health-care food function inspection and evaluation method (2023 edition) by combining the research results that beta-1, 3 / alpha-1, 3-glucan has the stimulation effect on small intestine peristalsis, promotes the growth of intestinal beneficial bacteria and regulates intestinal health in the existing research. The invention provides a new direction for preparing the medicine for treating and / or preventing obesity and / or body weight super-severe illness and health-care food beneficial to digestion.

A combination therapy including both intranasal and oral solid-form preparations is described. In combination, the intranasal and oral delivery pathways provided an enhancement in appetite suppression and associated weight loss in comparison to either intranasal or oral solid-form therapy alone. It was unexpected that the observed substantial increase and increase in rate of weight loss would be observed for the combination therapy, which on average provided a nearly 12% reduction in total body weight over the three-month trial.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention discloses a mulberry leaf extract for reducing body weight based on blood sugar regulation and a preparation method thereof, and belongs to the technical field of natural product extraction. The mulberry leaf extract is mulberry leaf DNJ, and the extraction and preparation steps of the mulberry leaf extract comprise pretreatment, composite enzymatic hydrolysis, ultrafiltration purification, resin adsorption and freeze-drying molding. By optimizing enzymolysis conditions and a separation and purification process, the extraction rate (gt; and therefore, a foundation is laid for industrial production. DNJ reduces blood sugar and body weight by promoting secretion of GLP-1, when DNJ is combined with GLP-1RA for use, a remarkable synergistic effect is shown, and the effects of reducing blood sugar and losing weight are further enhanced. The invention provides a natural and safe blood glucose reducing and weight losing active component and a preparation method thereof, provides a novel solution for treating diabetes and obesity, and has important social and economic values.

This disclosure provides methods for treating a condition or disease associated with weight gain that include administration of an apelin receptor agonist alone or in combination with a GLP-1 receptor agonist. Methods for increasing total weight loss in the subject relative to weight loss that would be caused by administration of a pre-determined amount of a GLP- 1 receptor agonist alone are also provided. In some embodiments, the method is for preserving, or maintaining muscle mass, muscle function, and / or muscle strength in a subject undergoing weight loss therapy. Also provided are method of treating diabetes or diabetic obesity. Also provided are method of treating heart failure with preserved ejection fraction. Also provided are pharmaceutical compositions, such as fixed dose combinations, that include an apelin receptor agonist and a GLP-1 receptor agonist. In some embodiments, the pharmaceutical composition is formulated for oral administration.

Methods and compositions promote weight loss in mammals, such as in humans and / or animals, such as, for example, pets. Specifically, the methods and compositions herein promote weight loss due to the production of appetite-suppressing gut hormones, increased metabolism, reduced fat and carbohydrate absorption, and reduced fat deposition through the synergistic combination of fibers and botanical extracts. Food products comprising the compositions herein provide a natural and effective means of controlling appetite and managing weight.

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.

The disclosure provides methods and uses of CCL5 variants for modulating GPR75 signaling in a cell or subject, treating a GPR75-related disease or disorder in a subject, treating obesity, hypertension, metabolic syndrome, metabolic dysfunction-associated steatohepatitis, and / or diabetes in a subject, and inducing weight loss and / or preventing weight gain in a subject, wherein the CCL5 variant comprises a variant N-terminal portion and a C-terminal portion with at least 70% identity to the corresponding portion of wild type CCL5.

The present invention relates to pharmaceutical combinations for treating or preventing insulin resistance and associated disorders, in particular the use combinations comprising a 4-epimerase inhibitor and a GLP-1 receptor agonist for treating or preventing insulin resistance and associating disorders such as obesity and type-2 diabetes, supressing appetite and / or promoting weight loss.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

The invention relates to a composition with fat burning accelerating and weight losing effects and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problems that an existing classic prescription, namely the three-kernel decoction, is laggard in process and large in dosage are solved. The composition consists of the following traditional Chinese medicine extracts in parts by mass: 1-5 parts of a traditional Chinese medicine extract A, 4-7 parts of a traditional Chinese medicine extract B, 6-8 parts of a traditional Chinese medicine extract C and 3-9 parts of a traditional Chinese medicine extract D. According to the composition disclosed by the invention, the classical prescription of the Sanjing decoction is applied, the effective components are extracted and separated through modern science and technology to obtain an effective extract, the curative effect is exerted through a corresponding proportion, and pharmacodynamic research shows that the traditional Chinese medicine composition disclosed by the invention can achieve the effects of accelerating fat burning and losing weight through the effects of diminishing swelling, clearing damp, draining water and expelling toxin. And the related process is advanced, and the dose is not large.

This item is notebook paper used for recording neonatal jaundice and physiological weight loss.

The present invention provides a method for predicting the tendency of weight loss in Equus animals by evaluating multiple markers in a sample obtained from an Equus animal. Such markers include fermentation products and / or their metabolites, such as volatile fatty acids, bacterial population diversity indicators, and the abundance / relative abundance of specific bacterial taxa.

Formulations of HDAC6 inhibitors that traverse the blood brain barrier in the hypothalamus and inhibit HDAC6 in arcuate AgRP neurons in the hypothalamus are effective for causing weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin resistant individuals.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

Disclosed herein is a deuterated compound of Formulas (I) and (II) as an FTO inhibitor with improved pharmacokinetic properties with comparable selective FTO inhibition. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

The invention discloses a weight losing scheme generation method and system based on food share and exercise data, and the method comprises the steps: obtaining daily recommended intake energy data based on weight data and physical activity type data; distributing the daily recommended intake energy data to obtain share quantity data of each type of food; calculating according to the gender data, the age data, the height data and the weight data to obtain basal metabolic rate data; calculating physical activity energy consumption data according to the daily weight loss target data, the daily recommended intake energy data and the basal metabolic rate data; inputting the physical activity energy consumption data and the expected exercise type data into an energy consumption calculation formula to obtain daily activity duration data; and generating a weight losing plan based on the share quantity data of each type of food, the daily exercise type and the exercise duration data. According to the method, the user can be helped to efficiently reduce weight and maintain body health.

The invention discloses a functional solid beverage capable of reducing fat, losing weight and conditioning five highs. According to the functional solid beverage, dietary fibers such as fructo-oligosaccharide, inulin and the like are used for regulating intestinal flora, a white kidney bean extract is used for inhibiting the activity of alpha-amylase, L-carnitine is used for promoting fat transport, and medicinal and edible components such as ginseng, lotus leaves and the like are matched to realize multi-way metabolism regulation. The weight percentage of each component can be adjusted within a specified range so as to adapt to different physique requirements. Animal experiments prove that the total cholesterol (TC) of serum can be obviously reduced by 21.3-25.8% and the triglyceride (TG) can be obviously reduced by 28.9-34.2% after the traditional Chinese medicine is continuously taken for 4 weeks, and meanwhile, the insulin resistance index (HOMA-IR) can be improved to 16.5-20.3%.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The name of the invention is compositions and methods for enhancing cancer radiotherapy. A nutritional supplement comprising fish oil and selenium has been determined to enhance radiotherapy of tumors in a synergistic manner. The co-therapy of such supplements and radiotherapy results in a significantly improved reduction in tumor volume in animal models and reduces the common side effects, such as weight loss, inflammation and gastrointestinal tract damage, relative to radiotherapy alone. It has also been found that this co-therapy can reduce the incidence of metastasis from a primary implant site and modulate the expression of genes associated with apoptosis in tumor cells. Formulations of such supplements with good tolerance and palatability are also provided.

Predicting a weight loss potential from gut microbiome data is described herein. In an example, a system accesses gut microbiome metagenomic sequence data for a subject and determines a measurement of one or more weight loss features from the gut microbiome metagenomic sequence data. The one or more weight loss features define a gut microbiome signature for weight loss response for the subject independent of a body mass index of the subject. The system determines a weight loss potential for the subject based on a comparison of the measurement of the subject to a plurality of reference measurements of the one or more weight loss features for a reference population showing variable weight loss responses. The system outputs the weight loss potential for the subject.

To provide modified or polymer conjugated MetAP2 inhibitors.SOLUTION: The present invention relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.SELECTED DRAWING: Figure 1

The present invention provides nutritional compositions for use in weight loss dietary interventions or in particular weight maintenance after dietary interventions, preferably after low calorie dietary interventions. The nutritional composition comprises one or more amino acids selected from the group consisting of proline, histidine, glycine and / or hydroxyproline, or a combination thereof, which can be used to assist in weight loss in obese subjects that are resistant to weight loss only by means of caloric limiting dietary intervention. In addition, the nutritional composition of the present invention may be used to help maintain the weight loss, particularly after dietary intervention.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The invention provides an application of a tartary buckwheat antioxidant peptide in preparation of weight-reducing drugs, the tartary buckwheat antioxidant peptide (SEQ ID NO: 1) is used for reducing triglyceride and total cholesterol levels in serum and reducing body weight, and the tartary buckwheat antioxidant peptide is used for preparation of drugs for reducing blood fat and preparation of weight-reducing nourishment or drugs. The tartary buckwheat antioxidant peptide achieves the purpose of losing weight by reducing body weight and blood fat, and a new example is provided for the development of food-borne weight-losing nourishments or medicines and the clinical application of the tartary buckwheat antioxidant peptide.